Deka Bank Deutsche Girozentrale Clovis Oncology, Inc. Transaction History

Deka Bank Deutsche Girozentrale

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2021 Feb 02, 2022	SELL	$2.7 - $4.76 $75,600 - $133,280	-28,000 Closed	0 $0
Q4 2020 Mar 12, 2021	BUY	$4.13 - $6.41 $115,640 - $179,480	28,000 New	28,000 $123,000
Q1 2020 May 14, 2020	SELL	$3.77 - $11.0 $31,626 - $92,279	-8,389 Closed	0 $0
Q4 2019 Feb 04, 2020	SELL	$3.0 - $16.43 $55,800 - $305,598	-18,600 Reduced 68.92%	8,389 $95,000
Q3 2019 Nov 14, 2019	SELL	$3.93 - $15.35 $73,098 - $285,510	-18,600 Reduced 40.8%	26,989 $108,000
Q2 2019 Aug 01, 2019	BUY	$12.81 - $25.67 $272,289 - $545,641	21,256 Added 87.35%	45,589 $616,000
Q1 2019 May 10, 2019	BUY	$17.66 - $30.28 $65,342 - $112,036	3,700 Added 17.93%	24,333 $871,000
Q4 2018 Feb 12, 2019	SELL	$11.63 - $32.67 $43,031 - $120,879	-3,700 Reduced 15.21%	20,633 $371,000
Q3 2018 Nov 09, 2018	BUY	$29.37 - $49.48 $17,122 - $28,846	583 Added 2.45%	24,333 $0
Q1 2018 May 03, 2018	SELL	$50.12 - $67.72 $1.21 Million - $1.63 Million	-24,050 Reduced 50.31%	23,750 $1.26 Million
Q3 2017 Nov 06, 2017	BUY	$67.17 - $84.81 $3.21 Million - $4.05 Million	47,800	47,800 $3.43 Million

166

Ticker CLVS
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 144,480,000
Market Cap $13M
Description
Clovis Oncology, Inc., a biopharmaceutical company, focuses on acquiring, developing, and commercializing anti-cancer agents in the United States, Europe, and internationally. In the U.S., the company offers Rubraca (rucaparib), an oral small molecule inhibitor of poly ADP-ribose polymerase for recurrent epithelial ovarian, fallopian tube, or pr...

Get notified when there are updates to the investment portfolio of Deka Bank Deutsche Girozentrale, based on Form 13F filings with the SEC.

Stay updated on Deka Bank Deutsche Girozentrale with notifications on news.